Anteris Technologies Global Corp. (AVR)
NASDAQ: AVR · Real-Time Price · USD
3.430
+0.050 (1.48%)
Nov 21, 2025, 1:19 PM EST - Market open
AVR Revenue
Anteris Technologies Global had revenue of $429.00K in the quarter ending September 30, 2025, a decrease of -44.21%. This brings the company's revenue in the last twelve months to $2.14M, down -21.11% year-over-year. In the year 2024, Anteris Technologies Global had annual revenue of $2.70M, down -1.17%.
Revenue (ttm)
$2.14M
Revenue Growth
-21.11%
P/S Ratio
65.10
Revenue / Employee
$15,728
Employees
136
Market Cap
139.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.70M | -32.00K | -1.17% |
| Dec 31, 2023 | 2.74M | -384.72K | -12.33% |
| Dec 31, 2022 | 3.12M | -2.55M | -44.93% |
| Dec 31, 2021 | 5.66M | 203.73K | 3.73% |
| Dec 31, 2020 | 5.46M | -6.54M | -54.48% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AVR News
- 4 days ago - Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves - GlobeNewsWire
- 8 days ago - Anteris Announces Results for the Third Quarter of 2025 - GlobeNewsWire
- 24 days ago - Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”) - GlobeNewsWire
- 25 days ago - Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025 - GlobeNewsWire
- 2 months ago - Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders - GlobeNewsWire
- 2 months ago - Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders - GlobeNewsWire
- 3 months ago - Anteris Announces Results for the Second Quarter of 2025 - GlobeNewsWire
- 5 months ago - Anteris Appoints David Roberts and Gregory Moss to its Board of Directors - GlobeNewsWire